23rd May 2022 20:21
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Says it is making progress with two lead clinical stage programmes focused on diabetes. Says phase one clinical trial data for both lead product, AT247, an ultra-rapid insulin and for second product AT278, a concentrated rapid insulin targeting patients who require higher volumes of insulin, "excelled our expectations".
Chair Andrew Richards says: "We believe that our products will provide that key to unlock the future treatment landscape for diabetes. With our partnered portfolio continuing to attractive high calibre pharmaceutical companies and strong support from our shareholders following our successful IPO on the London Stock Exchange last year, we believe that Arecor is well positioned to both deliver on existing programmes and attract new and exciting opportunities in the coming year to create long-term shareholder value."
Current stock price: 363.00 pence
12-month change: up 50%
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Arecor Therape